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M A J O R A R T I C L E
Shiga Toxin–Producing Escherichia coli in Montana:
Bacterial Genotypes and Clinical Profiles
Jill K. Jelacic,1 Todd Damrow,4 Gilbert S. Chen,1 Srdjan Jelacic,3 Martina Bielaszewska,7 Marcia Ciol,3
Humberto M. Carvalho,5 Angela R. Melton-Celsa,5 Alison D. O’Brien,5 and Phillip I. Tarr2,3,6
1University of Washington School of Medicine, 2Departments of Pediatrics and Microbiology, University of Washington School of Medicine,
and 3Children’s Hospital and Regional Medical Center, Seattle, Washington; 4Montana Department of Public Health and Human Services, Helena;
5Uniformed Services University of the Health Sciences, Bethesda, Maryland; 6Division of Pediatric Gastroenterology and Nutrition, Edward
Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri; 7Institut für Hygiene, Universitätsklinikum
Münster, Münster, Germany
The diseases and virulence genes associated with Shiga toxin–producing Escherichia coli (STEC) are charac-
terized incompletely. We analyzed, by polymerase chain reaction, 82 STEC isolates collected prospectively in
Montana and profiled associated illnesses by patient chart review. All E. coli O157:H7 contained stx2-group
genes, as well as eae, iha, espA, and ehxA; 84% contained stx1. Non-O157:H7 STEC less frequently contained
stx1 ( ), stx2 ( ), iha ( ), eae, and espA ( for both), were isolated less often fromP p .046 P ! .001 P ! .001 P p .039
patients treated in emergency departments ( ), and tended to be associated less frequently with bloodyP p .022
diarrhea ( ). There were no significant associations between stx genotype and bloody diarrhea, butP p .061
isolates containing stx2c or stx2d-activatable were recovered more often from patients who underwent diagnostic
or therapeutic procedures ( ). Non-O157:H7 STEC are more heterogeneous and cause bloody diarrheaP p .033
less frequently than do E. coli O157:H7. Bloody diarrhea cannot be attributed simply to the stx genotype of
the infecting organism.
Many different Escherichia coli produce Shiga toxin
(Stx). Stxs belong to 1 of 2 groups. Stx1 [1] is nearly
identical to Stx, the principal extracellular cytotoxin
produced by Shigella dysenteriae serotype 1. Members
of the Stx2 group (Stx2, Stx2c, Stx2d, Stx2d-activatable, Stx2e,
and Stx2f) [2–5] have sequences that are less similar to
Stx. E. coli O157:H7 is the best known and the most
frequently isolated of the Stx-producing E. coli (STEC);
the comparatively high rate of isolation and promi-
nence of this serotype is attributable, at least in part,
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to its inability to ferment sorbitol [6]. When plated on
MacConkey agar that contains sorbitol in lieu of lactose,
E. coli O157:H7 appear as colorless colonies. This
non–sorbitol-fermenting phenotype is, therefore, an
easily distinguishable characteristic that can be sought
in economical and efficient screening protocols, if stool
samples are plated on sorbitol MacConkey (SMAC)
agar when they arrive in the laboratory [7]. However,
it will not detect most non-O157:H7 STEC, which gen-
erally ferment sorbitol, so such organisms are easily
overlooked.
The fact that E. coli O157:H7 causes diarrhea, bloody
diarrhea, and hemolytic-uremic syndrome (HUS) has
been well established since 1983, when E. coli O157:H7
was first associated with human disease [8, 9]. In con-
trast, the spectrum of illnesses associated with non-
O157:H7 STEC, the characteristics of patients from
whom they are isolated, the genotypes of these organ-
isms, and the extent to which these organisms are path-
ogenic to humans, are less well established [10]. How-
ever, several studies suggest that illnesses associated with
non-O157:H7 STEC differ from those caused by E. coli
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O157:H7, particularly in the lesser ability of the former group
of organisms to cause bloody diarrhea and HUS [4, 11–14].
The characteristics of STEC-induced illnesses in humans re-
late, presumably, to the genomic contents of the infecting
strains. Ostroff et al. [15] reported that E. coli O157:H7 that
contained stx2-group genes but that did not contain stx1 were
more likely to be isolated from patients with HUS than were
E. coli O157:H7 isolates containing both stx1 and stx2-group
genes. This trend was observed again in a recent prospective
study in the Pacific Northwest [16]. Indeed, Donohue-Rolfe et
al. [17] have reported that the removal of stx1 from an stx1
+/
stx2
+ E. coli O157:H7 isolate augments its virulence in gnoto-
biotic piglets. Boerlin et al. [12] reported a strong association
between the presence of stx2-group genes in human STEC from
8 major serotypes and the severity of associated disease. Fried-
rich et al. [4] refined stx genotype analysis by examining allelic
variants within the stx2 group and suggested that STEC con-
taining stx2d or stx2e were associated with less-severe disease or
were not pathogenic to humans.
STEC contain a repertoire of putative virulence loci, in ad-
dition to their stx genes. eae, which encodes intimin, is in the
locus of enterocyte effacement (LEE) [18] and is the best char-
acterized of the non-stx virulence loci. eae is necessary for
pathogenicity in several animal models of enteric infection
[19–21]. Additional candidate virulence loci in STEC include
other LEE genes, such as espA, which encodes a filamentous
organelle on the surface of E. coli O157:H7 [22], as does its
homologue in enteropathogenic E. coli [23]; iha, which is found
on the tellurite-resistance, adherence-conferring island and en-
codes a novel adhesin [18] in E. coli O157:H7 (a homologue
of Iha is found in the outer membranes of other STEC) [24];
and genes encoded on the large plasmid found in most pre-
sumptively pathogenic STEC, such as ehxA, which encodes the
enterohemorrhagic E. coli–hemolysin [25–29].
Studies that have attempted to associate STEC genotypes and
the characteristics of the illnesses in the patients from whom
these organisms were isolated have often analyzed existing
strain collections for the sake of convenience. Such selection
could lead to unintentional biases in analyses and conclusions.
In addition, there have been no detailed attempts to relate
bacterial genotypes to clinical manifestations of non-O157:H7
STEC in the United States, and the analyses of non-O157:H7
STEC infections from North America have consisted of small
numbers of patients or limited descriptions of their illnesses
[13, 30–34]. Here, we analyze STEC belonging to a variety of
serotypes that were collected from patients in Montana during
a defined interval in a statewide surveillance project. We also
profile the illnesses in the patients from whom these organisms
were recovered and attempt to determine whether there are
discernible associations between STEC genotype and illness
observed.
MATERIALS AND METHODS
Patient isolates. Between June 1998 and May 2000, all stool
samples submitted to each of 16 Montana microbiology labora-
tories (Billings Deaconess Clinic Health System and St. Vincent’s
Hospital, Billings; Bozeman Deaconess, Bozeman; Browning
Indian Health Service, Browning; St. James Hospital, Butte;
Crow Agency Indian Health Service, Crow Agency; Barrett Me-
morial Hospital, Dillon; Benefis Healthcare and Great Falls
Clinic, Great Falls; Northern Montana Hospital, Havre; St. Pe-
ter’s Hospital, Helena; Kalispell Regional Hospital, Kalispell;
Central Montana Medical Center, Lewiston; Holy Rosary
Health Center, Miles City; and Missoula Community Medical
Center and St. Patrick’s Hospital, Missoula) were evaluated for
the presence of Salmonella species, Shigella species, and Cam-
pylobacter jejuni at point of receipt and then were sent as swab
specimens in Cary-Blair transport media to the Montana State
Public Health Laboratory (Helena) for the isolation and iden-
tification of STEC.
After arrival at the reference laboratory, the swabs were re-
moved from the transport media and inoculated into 10 mL
of MacConkey broth. Broths then were incubated overnight at
35C. One hundred microliters of this culture was tested for
the presence of Stx by use of the Premier EHEC EIA kit (Me-
ridian Biosciences), according to the manufacturer’s instruc-
tions. Broths that produced a signal indicating the presence of
Stx were further cultured to standard MacConkey and to SMAC
agar plates. After overnight incubation at 35C, non–sorbitol-
fermenting colonies were tested for the presence of the O157
antigen by use of the Wellcolex O157:H7 STEC latex aggluti-
nation test (Abbott Laboratories). If non–sorbitol-fermenting
colonies were not observed or if the non–sorbitol-fermenting
colonies failed to react with the O157-specific antibody, 2 or 3
lactose-fermenting colonies were grown overnight in MacConkey
broth at 35C and were tested the next day for the production
of Stx by use of the Premier EHEC EIA kit on broth, as described
above.
Isolates that produced Stx in broth were confirmed to be E.
coli by use of a Vitek Junior Model 32 System J1733 analyzer
(BioMerieux Vitek). Somatic antigens 26, 104, 111, 121, and
157 were sought by agglutination for all STEC. An isolate was
considered to be motile if a line of diffuse emanation was
observed in motility media after inoculation and overnight in-
cubation. If an isolate did not grow diffusely from the inoc-
ulation line, it was considered to be nonmotile (NM). The
presence or absence of the H7 antigen was determined by use
of the Wellcolex E. coli latex agglutination test (Abbott Labo-
ratories) for all isolates that expressed the O157 lipopolysac-
charide. Isolates with undetermined O or H antigens were typed
at the Centers for Disease Control and Prevention (Atlanta)
for each of the 181 known O antigens and 52 of the 56 known
H antigens. Isolates that agglutinated completely with all O-
 at U
niversity of N
ebraka-L
incoln L
ibraries on A
ugust 2, 2012
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Shiga Toxin–Producing E. coli in Montana • JID 2003:188 (1 September) • 721
specific antisera were classified as “Orough,” because of their
self-agglutination phenotype. Isolates that were nonreactive in
E. coli O antigen antiserum pools were classified as “Onon-
typeable” (ONT).
Bacterial genotypes. Table 1 lists the primers for the
alleles sought, the polymerase chain reaction (PCR) condi-
tions, and the positive control strains for each primer pair
used in this study. The negative control for each reaction was
E. coli HB101 [35]. Bacteria were grown overnight in Luria-
Bertani broth [35]. Template DNA was prepared by adding
45 mL of bacterial broth culture to 5 mL of 0.1% Triton-X in
sterile Eppendorf tubes and by boiling the mixture for 20
min. dNTPs were purchased from Promega, and Taq DNA
polymerase and restriction endonucleases were purchased
from New England Biolabs. After amplification in a thermal
cycler (iCycler; Bio-Rad), PCR products were analyzed by
electrophoresis in 0.5 Tris-borate EDTA (TBE) [35] 1.5%
agarose, followed by ethidium-bromide staining. stx2 and stx2c
genes were preliminarily differentiated by restriction analysis
of the GK3-GK4 amplification products, using HaeIII and FokI
[36]. However, stx2c alleles are indistinguishable from stx2d-acti-
vatable genes (A.R.M.-C., unpublished observation) by the initial
PCR technique used in this study [36]; therefore, isolates with
apparent stx2c alleles were tested using stx2d-activatable primer pairs,
as noted in table 1, to generate an 890-bp amplicon. PstI cleaves
this amplicon into 504- and 386-bp fragments if the target gene
is stx2c, but does not cleave amplicons derived from stx2d-activatable.
Because the stx2-group amplicon of an E. coli O28ab:H28
failed to yield predicted fragments when digested with FokI or
HaeIII, we produced an amplicon that spans the genes encoding
the holotoxin, using primers 5′-CAAAGCAGCAATGGCGCT-
AGG-3′ and 5′-TTTCACCAGTCGCCCCTCCAC-3′, digested
the amplicon with EcoRV, modified the resulting fragments
using the A-tailing procedure (Promega), inserted them into
the pGEM-T Easy Vector (Promega), and sequenced them using
an ABI PRISM 377 DNA Sequencer (Applied Biosystems).
Then, we amplified a 382-bp amplicon spanning the presumed
EcoRV site by use of primers 5′-TACTGGGTTTTTCTTCG-
GTA-3′ and 5′-GTGGTATAACTGCTGTCCGT-3′, which also
was inserted into the pGEM-T Easy Vector and sequenced.
Activation assay. Two isolates that contained stx2d-activatable
as their sole stx genes were tested further, to determine whether
the Stx that they produced exhibited the activatable phenotype.
The activation assay was performed as described elsewhere [37].
In brief, culture supernatants from strains containing Stx2-type
toxins were incubated with mouse small-intestinal mucus or a
buffer control and incubated at 37C for 2 h. The cytotoxicity
of the toxin-mucus or toxin-buffer mixture then was measured
on Vero cells. The toxin is considered to be activatable if the
resulting cytotoxicity increases at least 8-fold after incubation
with the mouse mucus.
Clinical data. Clinical data were obtained by reviewing
the medical records of Montana residents from whom STEC
were isolated during the study period, after receiving permis-
sion from the Institutional Review Board of the University of
Washington Medical Center. Data recorded included age, sex,
date of first stool culture, site of first medical treatment, symp-
toms described in the chart (presence of blood in the stool,
abdominal pain, nausea, vomiting, fever, headache, and muscle
aches), laboratory results (white blood cell count and fecal
leukocytes), procedures performed, and antimicrobial agents
prescribed. A symptom was characterized as being present if it
was specifically mentioned as having been experienced by the
patient during the illness or as being absent if it was specifically
denied. If a symptom was neither specifically mentioned nor
specifically denied as being present, patients were not entered
into analysis for that variable. A procedure was defined as any
entry of a therapeutic or diagnostic device, including surgery,
into the body, excluding phlebotomies and bladder catheteri-
zations. If a procedure was not mentioned, it was characterized
as not having been performed. If an antimicrobial was not
specifically recorded in the chart, it was characterized as not
having been prescribed. All data obtained were entered into a
relational database for statistical analysis.
Statistics. We used the Wilcoxon rank sum test to assess
the significance of the difference between median ages of pa-
tients infected with E. coli O157:H7 and with non-O157:H7
STEC. The association between pairs of categorical variables
was assessed by Fisher’s exact test. Logistic regression was per-
formed to assess the association between the characteristics of
the infecting organism and the probability of bloody diarrhea.
RESULTS
STEC recovered. Between June 1998 and May 2000, ∼6300
stool samples were analyzed for STEC, as described above.
STEC were recovered from 85 of these stool samples, and 1
stool sample with a positive EIA result failed to yield an STEC
after further subculturing. Three patients whose stool samples
yielded STEC belonging to serotypes O121:H19, O124:H19, and
ONT:NM also were infected with C. jejuni. Because we were
unable to attribute these patients’ symptoms to the C. jejuni
or the non-O157:H7 STEC, these strains and the illnesses of
the patients from whom they were isolated were not entered
into analysis. Of the 82 remaining STEC, 31 (38%) were E. coli
O157:H7, and 1 (1%) was a non–sorbitol-fermenting E. coli
O157:NM. The 32 isolates expressing the O157 lipopolysac-
charide antigen were analyzed together as E. coli O157:H7.
Forty-one of the 50 non-O157:H7 STEC expressed 8 different
identifiable O antigens, 4 were Orough, and 5 were “Ounde-
termined” (table 2). Seventy-two percent and 63% of the re-
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Table 2. stx genotype of Shiga toxin–producing Escherichia coli (STEC) isolates in this study, by serotype, and
proportion with bloody diarrhea.
Serotype (no.)
Genotype, no. of isolates
Bloody
diarrheaa Proceduresb
Emergency
departmentcstx1 stx2 group stx2 stx2c stx2c2 stx2d-activatable
O157:H7 (31) 26 31 29 4 0 0 21/26 (81) 6 17
O157:NM (1) 1 1 0 1 0 0 1/1 (100) 1 1
O26:H11 (16) 16 0 0 0 0 0 5/11 (45) 1 7
O26:NM (2) 2 0 0 0 0 0 1/1 (100) 1 1
O28ab:H28 (1) 0 1 0 0 1 0 0/1 (0) 0 1
O28ac:H25 (1) 0 1 0 0 0 1 1/1 (100) 1 0
O73:H18 (1) 0 1 0 0 0 1 1/1 (100) 0 0
O103:H2 (1) 1 0 0 0 0 0 0/1 (0) 0 0
O103:H25 (1) 1 0 0 0 0 0 0/1 (0) 0 0
O119:H4 (15) 1 0 0 0 0 0 NA 0 0
O121:H19 (15) 1 15 15 0 0 0 7/13 (54) 2 3
O145:NM (1) 1 0 0 0 0 0 1/1 (100) 1 1
O165:H25 (1) 0 1 0 1 0 1 1/1 (100) 1 1
O177:NM (1) 1 1 0 1 0 0 1/1 (100) 0 0
O181:H49 (1) 0 1 1 0 0 0 1/1 (100) 0 0
Orough:H2 (1) 1 0 0 0 0 0 NA 0 0
Orough:H11 (2) 2 0 0 0 0 0 1/1 (100) 0 0
Orough:H18 (1) 1 1 1 0 0 0 NA 0 0
ONT:H25 (2) 2 1 1 0 0 0 NA 1 0
ONT:NM (1) 1 0 0 0 0 0 1/1 (100) 0 0
Total 58 55 47 7 1 3 43/63 (68) 15 32
NOTE. NA, symptoms not addressed for patients whose stool samples yielded these STEC.
a Data are no. reporting diarrhea/no. whose history addressed this symptom (%).
b Procedures performed on 7 patients in the E. coli O157:H7 group consisted of 1 appendectomy, 2 sigmoidoscopies, and 4 colo-
noscopies. Procedures performed on 8 patients in the non-O157:H7 STEC group consisted of 2 appendectomies (O26:H11 and ONT:
H25), 2 sigmoidoscopies (O28ac:H25 and O121:H19), 3 colonoscopies (O121:H19, O145:NM, and O165:H25), and 1 esophagogastro-
duodenoscopy and colonoscopy (O26:NM).
c Data are no. of patients whose cultures were submitted from an emergency department.
coveries of E. coli O157:H7 and non-O157:H7 STEC, respec-
tively, occurred between June and October, inclusive.
Patients whose stool cultures yielded O157:H7 STEC had a
tendency to report bloody diarrhea more frequently at presen-
tation ( ) and to have had their cultures obtained inP p .061
an emergency department ( ). Patients infected withP p .022
E. coli O157:H7 were older than those infected with non-O157:
H7 STEC (median age, 16.7 years [range 2.6–68 years] vs. 10.0
years [range, 0.6–87 years]; , Wilcoxon rank sum test).P p .19
Otherwise, the characteristics of patients whose stool sample
contained E. coli O157:H7 were similar to those whose stool
samples contained non-O157:H7 STEC (table 3).
stx alleles, E. coli O157:H7 vs. non-O157:H7 STEC. All E.
coli O157:H7 contained stx2-group genes. Twenty-seven (84%)
contained, in addition, stx1. Two E. coli O157:H7 contained stx2c
as their only stx2-group allele, and 2 contained stx2c in addition
to stx2. None of the stx2c genes in E. coli O157:H7 were determined
after subsequent analysis to be an stx2d-activatable variant.
Of the 50 non-O157:H7 STEC, 27 contained stx1 but not
stx2-group genes, 19 contained stx2-group genes but not stx1,
and 4 contained both stx1 and stx2-group genes. Four contained
stx2c on preliminary analysis, but after subsequent analysis, 3
of these isolates contained stx2d-activatable genes, 1 in combination
with an stx2c gene.
Non-stx alleles, E. coli O157:H7 vs. non-O157:H7 STEC.
Non-O157:H7 STEC contained iha, eae, and espA significantly
less frequently than the E. coli O157:H7 in this study, and none
of the 3 non-O157:H7 STEC with stx2d-activatable genes contained
eae or espA. Nonetheless, half or more of the non-O157:H7
STEC isolates in the present study did possess each non-stx
locus sought.
Genotypes and bloody versus nonbloody diarrhea. Of the
50 patients infected with non-O157:H7 STEC, 15 denied and 21
reported having had bloody diarrhea. Of these 36 patients for
whom the presence or absence of bloody diarrhea could be as-
sessed, non-O157:H7 STEC containing stx2 -group genes were
recovered from 7 of the 15 patients without bloody diarrhea and
from 12 of the 21 patients with bloody diarrhea ( ).P p .736
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Table 3. Comparison of clinical characteristics of patients in-
fected with Escherichia coli O157:H7 and non-O157:H7 Shiga
toxin–producing E. coli (STEC).
Variable
E. coli
O157:H7 group
Non-O157:H7
STEC group Pa
Male 12/32 (38) 30/50 (58) .070
Headache 0/2 (0) 2/4 (50) .467
Fecal leukocytes 20/26 (77) 20/29 (69) .558
Procedure 7/32 (22)b 8/50 (16)b .565
Antibiotics 11/32 (34)c 20/50 (38)b .648
First site
Emergency department 18/32 (56) 15/50 (30) .022
Other ambulatory facility 14/32 (44) 35/50 (70)
Bloody diarrhea 22/27 (81) 21/36 (58) .061
Abdominal pain 24/27 (89) 33/40 (83) .728
Nausea 8/13 (62) 8/12 (67) 1.0
Vomiting 8/20 (40) 15/29 (52) .562
Fever (% of “yes”) 7/23 (30) 8/35 (26) .553
sx1 27/32 (84) 31/50 (62) .046
stx2-group alleles 32/32 (100) 23/50 (46) !.001
stx2 allele 29/32 (91) 18/50 (78) !.001
stx2callele 5/32 (16) 2/50 (8) .104
stx2c2 allele 0/32 (0) 1/50 (2) 1.0
stx2d-activatable allele 0/32 (0) 3/50 (6) .277
stx1 or stx2 group
stx1 only 0/32 (0) 27/50 (54) !.001
stx2- group only 5/32 (16) 19/50 (38) .046
stx1and stx2 group 27/32(84) 4/50 (8) !.001
eae 32/32 (100) 43/50 (86) .039
espA 32/32 (100) 43/50 (86) .039
ehxA 32/32 (100) 44/50 (88) .077
iha 32/32 (100) 25/50 (50) !.001
NOTE. For symptoms, data are no. of patients who mentioned that symp-
tom was present/no. who mentioned or denied symptom (%). For genotypes,
data are no. of isolates with specific genotypes/all isolates tested (%).
a Two-tailed P (Fisher’s exact test). Significant values are in bold type.
b Procedures performed on 7 patients in the E. coli O157:H7 group con-
sisted of 1 appendectomy, 2 sigmoidoscopies, and 4 colonoscopies. Pro-
cedures performed on 8 patients in the non-O157:H7 STEC group consisted
of 2 appendectomies (O26:H11 and ONT:H25), 2 sigmoidoscopies (O28ac:
H25 and O121:H19), 3 colonoscopies (O121:H19, O145:NM, and O165:H25),
and 1 esophagogastroduodenoscopy and colonoscopy (O26:NM).
c Antibiotics administered to patients in the E. coli O157:H7 group included
amoxicillin, cephalexin, ciprofloxacin, metronidazole, and trimethoprim-sulfa-
methoxazole. Antibiotics administered to patients in the non-O157:H7 STEC
group included ampicillin, ceftriaxone, ciprofloxacin, erythromycin-sulfisoxazole,
furazolidone, metronidazole, and trimethoprim-sulfamethoxazole.
Non-O157:H7 STEC containing stx1 were recovered from 10 and
9 of these patient groups, respectively ( ). Of interest, ofP p .192
the 12 patients whose stool samples yielded E. coli O26 (none
of which contained stx2 -group genes) and whose history ad-
dressed whether or not they had bloody diarrhea, 6 reported that
this symptom was present. One isolate from these 36 patients
(ONT:NM) contained stx1 and stx2, and that patient had bloody
diarrhea. Of the 22 patients infected with E. coli O157:H7 who
reported bloody diarrhea, 4 were infected with stx1
/stx2-group
+
E. coli O157:H7, and 18 were infected with stx1
+/ stx2-group
+ E.
coli O157:H7. Each of the 5 patients infected with E. coli O157:
H7 who specifically denied bloody diarrhea was infected with
stx1
/stx2-group
+ E. coli O157:H7 ( ). Thus, there is noP p .56
statistically significant association between stx group and the pres-
ence or absence of bloody diarrhea.
Each of the 2 patients with stx2c
+ non-O157:H7 STEC re-
ported having bloody diarrhea, as did each of the 4 patients
whose stool samples contained stx2c
+ E. coli O157:H7. Of in-
terest, 4 of the 8 patients in this study whose infecting STEC
contained variant stx2 alleles (stx2c, stx2d-activatable, or both) un-
derwent invasive procedures, compared with only 11 of 74
patients infected with STEC without these alleles ( ).P p .033
We next assessed the relationship between each of the genes
sought and the presence or absence of bloody diarrhea, using
logistic regression analysis and restricting analysis only to the
patients whose stool samples yielded non-O157:H7 STEC.
Bloody diarrhea (“yes” vs. “no”) was the response variable, and
the explanatory variable was whether the test was positive or
negative for a certain characteristic. The last column of table
4 shows the P value of the test for the addition of the respective
characteristic to the logistic model.
Novel Stx sequence. Primers GK3 and GK4 produce from
E. coli O28ab:H28 a 270-bp amplicon that was cleaved by nei-
ther FokI nor HaeIII [36]. The gene encoding this B subunit
is the same length as the genes encoding the B subunits in stx2
and stx2c and is 6 bp longer than the genes encoding the B
subunits in stx2d, stx2e, and stx2f (figure 1). Within the overlap
region, this gene’s sequence differs from stx2, stx2c, stx2d, stx2e,
and stx2f at 16, 10, 21, 51, and 64 sites, respectively. Each of
the 10 polymorphic sites, compared with stx2c, the most similar
allele in the database, is in the 3′ two-thirds of the gene, which
suggests intragenic recombination in its evolution. However,
only 1 of these sites resulted in a change in an amino acid,
compared with Stx2c. We have designated this E. coli O28ab:
H28 stx allele stx2c2 (GenBank accession no. AY095209).
DISCUSSION
This population-based, prospective study demonstrates that
non-O157:H7 STEC are less likely to be isolated from patients
with bloody diarrhea than are E. coli O157:H7. We speculated
previously that the higher frequency of bloody diarrhea among
patients infected with E. coli O157:H7 could be attributed to
the higher frequency of stx2 in this group of organisms [13,
30], especially in consideration of animal and in vitro studies
that demonstrate that Stx2 is the more toxic of the 2 Stxs [38,
39]. However, we did not confirm this association among the
non-O157:H7 STEC in this study, largely because one-third of
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Table 4. Logistic regression analysis using bloody diarrhea (“yes” or “no”) as the response
variable among the 36 patients whose stool samples contained non-O157:H7 Shiga toxin–
producing Escherichia coli (STEC), whose histories specifically addressed this symptom, and
the genotype of the recovered STEC.
Characteristic
Group without bloody
diarrhea (n p 15)
Group with bloody
diarrhea (n p 21)
P for logistic
regression
eae 14 (93) 19 (91) .461
espA 14 (93) 19 (91) .461
ehxA 13 (87) 19 (91) .722
iha 6 (40) 11 (52) .462
stx1 9 (60) 10 (48) .462
stx2 group (all alleles) 7 (47) 12 (57) .535
stx2 allele 6 (40) 8 (38) .908
stx2c allele 0 (0) 2 (10) .135
stx2c2 allele 1 (7) 0 (0) .181
stx2d-activatable allele 0 (0) 3 (21) .064
NOTE. Data are no. (%) of patients whose isolate had each genotype.
the patients whose stool cultures yielded non-O157:H7 STEC
containing stx1, but not stx2-group genes, reported observing
bloody diarrhea. Therefore, factors other than the stx genotype
are likely to be responsible for the bloody diarrhea observed
during STEC infections, a restatement of the conclusion
reached by Welinder-Olsson et al. [11]. This relationship is
obviously complex, and further elucidation awaits a more com-
plete enumeration of virulence loci and their allelic variants in
non-O157:H7 STEC.
Our findings are noteworthy for several additional reasons.
First, E. coli O121:H19 was isolated from an unexpectedly large
number of cases and was recovered nearly as frequently as E.
coli O26:H11. E. coli O121:H19 was associated with an epidemic
in Connecticut [40], but its causative role in that report was
based mainly on serologic testing and not on isolate recovery.
None of the cases we report here were clustered in time or
space, and their multicentric occurrence confounded attempts
at source linkage. The high frequency of this serotype in this
study contrasts with its rarity of isolation from patients in 2
recent large European series [4, 41].
Second, none of the serogroup O26 STEC isolated during
the present study harbored an stx2 gene, which is typically pre-
sent in an STEC O26 clonal subgroup that recently emerged
as a pathogen in Germany [42]. This result suggests that this
new O26 STEC subgroup has not yet spread to the North
American region covered by our study.
Third, we demonstrated that some alleles designated stx2c in
the detection protocol actually encoded a mucus-activatable
toxin [43] on the basis of restriction fragment analysis. Thus,
the stx2d-activatable allele may be more prevalent in human STEC
than previously realized. It should also be emphasized that stx2d
variants, as defined by the analytical PCR conditions of Pierard
et al. [44] and which were not found in this study, are distinct
from the genes encoding the protein designated as the Stx2d-
activatable toxin.
Fourth, we provide data suggesting that E. coli containing stx2c
and stx2d-activatable alleles are associated with more-severe gastro-
intestinal disease in the human host (as manifested by higher
frequencies of associated procedures), compared with patients
whose infected STEC harbors other stx alleles. stx2c was originally
identified as a variant toxin in E. coli O157:NM [45], but in vitro
and mouse lethality testing failed to demonstrate enhanced viru-
lence of Stx2c, compared with other Stx2 alleles [46]. Compared
with Stx, Stx2c binds to a distinct, but overlapping, epitope on
globotriaosylceramide, the glycosphingolipid receptor for Stxs on
eukaryotic cells [47]. Furthermore, parenterally administered
VT2c, which is identical to Stx2c, preferentially binds to gut tissue,
especially cecal tissue, in rabbits and causes severe hemorrhagic
diarrhea [48], but it is probable that human gut has a different
distribution of Stx receptors. Although the inference that E. coli
containing stx2c are more virulent for humans than those with
other stx2 alleles requires confirmation, it is worth noting that
stx2c was the only stx2 variant identified in STEC from patients
with HUS in a recent German study [4].
Fifth, surveillance efforts for non-O157:H7 STEC probably
should include points of care other than emergency depart-
ments. In a recent study based largely on data gathered in an
emergency department, E. coli O157:H7 were recovered more
frequently than were non-O157:H7 STEC [13]. This discrep-
ancy probably is attributable to the more common occurrence
of bloody diarrhea in patients infected with E. coli O157:H7,
a symptom that conceivably precipitates urgent medical eval-
uation, and to the overall less-severe illnesses associated with
non-O157:H7 STEC. However, the possibility exists that non-
microbiologic factors, such as access to care and geographic
 at U
niversity of N
ebraka-L
incoln L
ibraries on A
ugust 2, 2012
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
726 • JID 2003:188 (1 September) • Jelacic et al.
Figure 1. Comparison of stx2 B subunit allele nucleotide sequences currently available in the National Center for Biotechnology Information Database
(available at: http://www.ncbi.nlm.nih.gov) with new stx2c2 B subunit allele from Escherichia coli O28ab:H28. GenBank accession nos. of respective B
subunits are provided in parentheses. Shaded nucleotides represent designated endonuclease sites in reference strains.
patient catchment patterns, influence the sites of presentation
to care of these Montana residents.
Finally, we identified a new allele, stx2c2, which most closely
resembles stx2c. Designation of Stx2c2 as a bona fide and novel
Stx2 variant awaits biologic studies that differentiate it from
Stx2c [49]. However, although the DNA sequence suggests the
novelty of this allele, Stx2c2 differs from Stx2c by only a single
amino acid.
Despite the geographically and temporally well-defined pop-
ulation investigated, our study has several limitations. First, we
relied on a retrospective analysis of charts to ascertain symp-
toms; such a data set is less complete than one collected pro-
spectively. We do not know whether nonmention of symptoms
reflects nonseverity, or the extent to which the conclusions
would have been different had data collection been prospective
and more complete. Second, the study structure did not permit
an assessment of the rate of development of HUS, because of
the lack of standardized follow-up. We were also unable to
examine the effect of antibiotics, which were administered to
large subsets of patients in both groups, on outcome. Third,
the possibility exists that STEC that were present were not
recovered. The shipment of stool samples to a central laboratory
might have diminished STEC viability while in transport. In
addition, our protocol of evaluating only sorbitol-fermenting
colonies for the ability to produce Stx if a serologic test for
colonies that did not express the O157 antigen was negative
would have overlooked unusual non-O157:H7 STEC that fail
to ferment sorbitol, such as E. coli O104:H21 [50]. Furthermore,
the study is biased toward the detection of STEC that produce
Stx that are detected in the EIA identification employed. How-
ever, this methodology might not have detected all Stx1 [41]
and Stx2 [4] variants, which are produced more frequently by
non-O157:H7 STEC than by E. coli O157:H7. Reduced Stx
expression in vitro and antigenic variation in Stx structure
could conceivably compromise the sensitivity of EIA. Vero cell
assays, or nucleic acid detection methodologies, might more
sensitively identify STEC that produce variant Stxs. Fourth,
because stool samples were not uniformly plated initially on
SMAC agar for E. coli O157:H7, some patients infected with
this serotype might have gone undetected, because EIA is less
sensitive than SMAC agar screening for the detection of this
pathogenic serotype [13]. Fifth, it is possible that some of these
cases represented undetected clustering of illnesses and that the
strain and trait distributions are skewed by duplicate analyses
of what is, in reality, the same organism. Sixth, because of the
heterogeneity of virulence factors among non-O157:H7 STEC,
it is important to note that the profiles of the illnesses associated
with these organisms might not apply to all populations, where
the distribution of causative serotypes might be different from
the one we observed in Montana during the study period.
Seventh, this heterogeneity also needs to be taken into account
when considering non-O157:H7 infections as a group, in com-
parison to E. coli O157:H7 infections. Although multiple studies
have demonstrated that, in aggregate, non-O157:H7 STEC are
associated with diminished frequency of bloody diarrhea and
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of HUS, compared with E. coli O157:H7, a subset of non-O157:
H7 STEC are probably as virulent as E. coli O157:H7.
A final limitation of this study is that we cannot state with
certainty that the non-O157:H7 STEC identified were the etio-
logic agents of the diarrhea, although we eliminated from analy-
sis patients whose stool samples yielded another bacterial en-
teric pathogen. The patients whose stool samples contained
non-O157:H7 STEC were plausibly made ill by them, but we
cannot assign a categorically pathogenic role to these organisms,
without control subjects. In this regard, it is noteworthy that,
in several studies that attempted to address the pathogenicity
of non-O157:H7 STEC, control subjects without diarrhea had
the same frequency of fecal excretion of non-O157:H7 STEC
as did patients with diarrhea [51–55]. Non-O157:H7 STEC are
quite common in food [56, 57], in contrast to the comparative
rarity of O157:H7 STEC [58]. Thus, human contact with non-
O157:H7 STEC is probably frequent, and it is possible that, in
some patients, the recovery of non-O157:H7 STEC in the stool
reflects innocuous gastrointestinal pass-though and not infec-
tion. Nonetheless, some of the many non-O157:H7 STEC with
which humans come in contact can cause epidemics [50,
59–61], and selected serotypes have well-substantiated associ-
ations with HUS [60, 62–64]. Furthermore, most of the non-
O157:H7 STEC in this study contained auxiliary, and probably
critical, virulence genes, such as eae, belong to serotypes that
have been associated with HUS and epidemics, and were in
comparatively high abundance among the patients’ aerobic co-
liform flora. It is, therefore, likely that most of the non-O157:
H7 identified in this study did, indeed, cause the enteric illnesses
in the patients from whom they were isolated. Clearly, a de-
finitive assessment and enumeration of the traits that are
needed to cause disease will facilitate the identification of which
of the many non-O157:H7 STEC are truly pathogens.
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